DualEntry | $90,000,000 | (Oct 7, 2025)
Voltai | $1,311,818 | (Oct 7, 2025)
NanoPhoria
Italy
- Milan, Lombardy
- 07/10/2025
- Series A
- $97,716,710
NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics.
The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle
which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes.
NanoPhoria’s lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.
- Industry Biotechnology
- Website https://www.nanophoria.com/
- LinkedIn https://www.linkedin.com/company/nanophoria/
Related People
Daniele CataluccCo Founder
Italy -
Greater Milan Metropolitan Area
Our lab aims to dissect the molecular mechanisms underlying cardiac diseases, to increase our knowledge about the function of the physiologic vs pathologic heart, and to develop novel and more effective therapeutic approaches for the treatment of the failing heart. To achieve this goal, we use multidisciplinary methodologies encompassing molecular and cellular biology, biochemistry, single- and multiple-cell functional assay, microscopy, nanotechnology, aptamer technology, and experimental models of cardiac disease.
Trogenix | $94,323,600 | (Oct 7, 2025)
SafeHill | $2,600,000 | (Oct 7, 2025)
Ansa Biotechnologies, Inc. | $54,400,000 | (Oct 7, 2025)
kiutra | $15,206,295 | (Oct 7, 2025)
Bee Maps (Powered by Hivemapper) | $32,000,000 | (Oct 7, 2025)
Cookiy AI | $7,000,000 | (Oct 7, 2025)
Cirrus Therapeutics | $11,000,000 | (Oct 7, 2025)
Hupside | $1,700,000 | (Oct 2, 2025)